Northwest Biotherapeutics (NWBO) Net Income towards Common Stockholders (2010 - 2026)

Northwest Biotherapeutics' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$3.4 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 82.66% year-over-year to -$3.4 million in Q1 2026; TTM through Mar 2026 was -$45.3 million, a 47.31% increase from a year earlier, with the FY2025 full-year figure at -$61.5 million, up 27.84% from the prior year.
• Net Income towards Common Stockholders retreated to -$3.4 million in Q1 2026 per NWBO's latest filing, from $1.3 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $1.3 million in Q4 2025 and bottomed at -$32.9 million in Q3 2022.
• The 5-year median for Net Income towards Common Stockholders is -$18.9 million (2024), against an average of -$18.8 million.
• Across the five-year window, Net Income towards Common Stockholders plunged 844.94% in 2022 and surged 104.39% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$28.3 million in 2022, then jumped by 49.4% to -$14.3 million in 2023, then sank by 99.02% to -$28.5 million in 2024, then jumped by 104.39% to $1.3 million in 2025, then plunged by 371.78% to -$3.4 million in 2026.
• Per Business Quant, the three latest NWBO Net Income towards Common Stockholders figures stand at -$3.4 million (Q1 2026), $1.3 million (Q4 2025), and -$27.2 million (Q3 2025).